

## UNITED STATES PARTMENT OF COMMERCE **United States Patent and Trademark Office**

COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. UMRCH 175

HM12/0625

09/506,988

02/18/00

TANG

**EXAMINER** SEAMAN, D

Patrea L Pabst Arnall Golden & Gregory LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta GA 30309-3450

ART UNIT PAPER NUMBER 1625

DATE MAILED:

06/25/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

16	
, t	

## **Advisory Action**

Application No.	Applicant(s)
09/506,988	TANG ET AL.
Examin r	Art Unit
D. Margaret Seaman	1625

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 12 June 2001 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

	initiation (NOL) in compliance with or or N 1:114.	
	PERIOD FOR REPLY [check only a) or b)]	
a) [2 b) [		jection,
ave be 37 CFR b) abov	xtensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) an ieen filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The R 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final ove, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, ever a patent term adjustment. See 37 CFR 1.704(b).	e appropriate extension fee under Office action; or (2) as set forth in
1.	A Notice of Appeal was filed on Appellant's Brief must be filed within the period s 37 CFR 1.192(a), or any extension thereof (37CFR 1.191(d)), to avoid dismissal of the a	
2.🛛	The proposed amendment(s) will be entered upon the timely submission of a Notice of A with requisite fees.	Appeal and Appeal Brief
3.⊠	The proposed amendment(s) will not be entered because:	
	a) they raise new issues that would require further consideration and/or search. (see N	OTE below);
٠.	b) they raise the issue of new matter. (see Note below);	
(c)	they are not deemed to place the application in better form for appeal by materially issues for appeal; and/or	reducing or simplifying the
(d)	d) they present additional claims without canceling a corresponding number of finally	rejected claims.
_	NOTE:	
<b>4.</b> □ <i>i</i>	Applicant's reply has overcome the following rejection(s):	
5.	Newly proposed or amended claim(s) would be allowable if submitted in a separat canceling the non-allowable claim(s).	e, timely filed amendment
6.⊠	The a)☐ affidavit, b)☐ exhibit, or c)☒ request for reconsideration has been considered application in condition for allowance because: see attached sheet.	but does NOT place the
7.	The affidavit or exhibit will NOT be considered because it is not directed SOLELY to iss raised by the Examiner in the final rejection.	ues which were newly
8.🖾	For purposes of Appeal, the status of the claim(s) is as follows (see attached written exp	lanation, if any):
	Claim(s) allowed:	
	Claim(s) objected to:	
	Claim(s) rejected: 1-12.	
	Claim(s) withdrawn from consideration:	
9. 🔲	The proposed drawing correction filed on a) □ has b) □ has not been approved	by the Examiner.
10.	Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)	
11.	Other:	
	D. M. Prim	argaret Seaman ary Examiner nit: 1625

Application/Control Number: 09/506,988

Art Unit: 1625

Advisory Action

Page 2

1. This application was filed 18 February 2001. Claims 1-12 are under final rejection

(see paper #13, dated 8 March 2001).

2. The period for reply continues to run 3 MONTHS from the date of the final

rejection. Any extension of time must be obtained by filing a petition under 37

CFR 1.136(a) accompanied by the appropriate fee. The date on which the petition under

37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for

purposes of determining the period of extension and the corresponding amount of the

fee. A reply within the meaning of 37 CFR 1.113 must be timely filed to avoid

abandonment of this application.

3. The amendment filed 12 June 2001, paper #14, under 37 CFR 1.116 in reply to the

final rejection will be entered upon the filing of an appeal, but is not deemed to place

the application in condition for allowance. Upon the filing of an appeal and entry of the

amendment, the status of the claims would be as follows:

Allowed claim(s): none

Rejected claim(s): 1-12

Claim(s) objected to: none

Application/Control Number: 09/506,988

place the case in condition for allowance.

Art Unit: 1625

4. The amendment filed 12 June 2001, paper #14, under 37 CFR 1.116 in reply to the final rejection has been considered but is not deemed to place the application in condition for allowance and will not be entered because: The amendments do not place the application in condition for allowance. Applicants argue that the critical core structure necessary for enablement of the instant invention is well known. The core structure that Applicants refer to is the structure of the aspartic acid proteases. However, the core structure that is referred to in paper #13 is the structure of the compounds that inhibit the aspartic acid protease. This is what is lacking enablement. Applicant further argues that such compounds to inhibit aspartic acid protease are well known in the art. However, only single transition-state isosteres are known. Two or greater transition-state isosteres are not known and as such, need further enablement. Applicants argue that the pharmaceutical composition and method of treating are taught by the instant specification, however, only the pharmaceutical composition and method of treatment using the one compound disclosed by the specification is taught, specifically UIC-98-056. If no compounds are known to be applicable, then a higher level of enablement is required. Therefore, the instant amendments are not seen to

Page 3

5. The shortened statutory period for reply expires THREE MONTHS from the mailing date of the final rejection or as of the mailing date of this advisory action,

Art Unit: 1625

whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Any extension fee required pursuant to 37 CFR 1.17 will be calculated from the date that the shortened statutory period for reply expires as set forth above.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. Margaret Seaman whose telephone number is 703-308-4528. The examiner can normally be reached on 630am-4pm, First Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat can be reached on 703-308-2439. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

D. Margáret Seama Primary Examiner

Art Unit 1625

dms June 22, 2001